Loading
A phase 2 trial of Lutetium-177 vipivotide tetraxetan in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function is a phase 2 interventional study registered as NCT06004661 by Novartis Pharmaceuticals, with 23 participants enrolled, started 2024-04-04 and due to reach its primary completion in 2026-12-14. Interventions recorded: AAA617, 68Ga-PSMA-11. Conditions listed: Metastatic Castration-Resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lutetium-177 vipivotide tetraxetan, Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Total-body PET for personalised radioligand dosing, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Novartis.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Lutetium-177 vipivotide tetraxetan, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Radioligand therapy (beta emitters), Novartis, Prostate cancer.
Shares Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/